期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 19, 期 3, 页码 639-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2010.03.006
关键词
Adjuvant endocrine therapy; Tamoxifen; Aromatase inhibitors; Ovarian suppression
Adjuvant endocrine treatment is an essential component in therapy for hormone receptor positive breast cancer. Among postmenopausal patients, options include tamoxifen, aromatase inhibitors, or a sequence of these agents. Tamoxifen and aromatase inhibitors have distinctive side-effect profiles. Among premenopausal women, tamoxifen remains the standard treatment. The role of ovarian suppression in addition to tamoxifen is under investigation. Questions about the duration of adjuvant endocrine therapy, the use of biomarkers for treatment selection and prognosis, and the management of side effects of adjuvant endocrine therapy remain key areas of investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据